key: cord-0713619-cyufdhhn
authors: Turnbull, James; Jha, Rakesh; Ortori, Catherine A; Lunt, Eleanor; Tighe, Patrick J; Irving, William L; Gohir, Sameer A; Kim, Dong-Hyun; Valdes, Ana M; Tarr, Alexander W; Barrett, David A; Chapman, Victoria
title: Serum levels of pro-inflammatory lipid mediators and specialised pro-resolving molecules are increased in SARS-CoV-2 patients and correlate with markers of the adaptive immune response
date: 2022-01-03
journal: J Infect Dis
DOI: 10.1093/infdis/jiab632
sha: ff0f7d6a690bbbe7c6da2816b843a67538718456
doc_id: 713619
cord_uid: cyufdhhn

BACKGROUND: Specialised pro-resolution molecules (SPMs) halt the transition to chronic pathogenic inflammation. We aimed to quantify serum levels of pro- and anti-inflammatory bioactive lipids in SARS-CoV-2 patients, and to identify potential relationships with innate responses and clinical outcome. METHODS: Serum from 50 hospital admitted inpatients (22 female, 28 male) with confirmed symptomatic SARS-CoV-2 infection and 94 age and sex matched cohort collected prior to the pandemic (SARS-CoV-2 negative), were processed for quantification of bioactive lipids and anti-nucleocapsid and anti-spike quantitative binding assays. RESULTS: SARS-CoV-2 serum had significantly higher concentrations of omega-6 derived pro-inflammatory lipids and omega-6 and omega-3 derived SPMs, compared to age and sex matched SARS-CoV-2 negative group, which were not markedly altered by age or sex. There were significant positive correlations between SPMs, pro-inflammatory bioactive lipids and anti-spike antibody binding. Levels of some SPMs were significantly higher in patients with an anti-spike antibody value >0.5. Levels of linoleic acid (LA) and 5,6-dihydroxy-8Z,11Z,14Z-eicosatrienoic acid (5,6-DHET) were significantly lower in SARS-COV-2 patients who died. DISCUSSION: SARS-COV-2 infection was associated with increased levels of specialised pro-resolution molecules and other pro- and anti-inflammatory bioactive lipids, supporting the future investigation of the underlying enzymatic pathways, which may inform the development of novel treatments.

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterised by fever and cough, with more severe cases developing acute respiratory distress, acute lung injury, pneumonia, and mortality [1] [2] [3] . The higher rates of severe SARS-CoV-2 illness and death are associated with increasing age [4, 5] . SARS-CoV-2 infection is associated with changes in adaptive and innate immunity, including elevated levels of circulating neutrophils and in severe cases the presence of peripherally derived macrophages in the lungs [6, 7] , reduced numbers of circulating T cells [8] and robust cytokine responses, which continues after clearance of the virus [9] . SARS-CoV-2 infection is also associated with elevated levels of prostaglandins (PGs) [10, 11] , albeit these levels decrease with severe disease [11] , and pro-inflammatory cytokines, including IL6, IL1β, and TNF [12, 13] . Importantly, levels of anti-inflammatory cytokines IL4 and IL10 are also elevated following infection [12] .

PGs and leukotrienes have essential roles in initiating acute inflammatory responses and the generation of pro-inflammatory cytokines, which sustain chronic inflammatory responses. In concert with these cyclooxygenase (COX) pathways, the lipoxygenase (LOX) pathways produce pro-inflammatory hydroxyeicosatetraenoic acids (HETEs) from arachidonic acid (AA) and hydroxyoctadecadienoic acids (HODEs) from LA. The active curtailing of inflammatory signalling is essential to restore tissue homeostasis and prevent chronic inflammatory events leading to pathology [14] . Following the initial acute inflammatory phase, specialised pro-resolving molecules (SPMs), derived from key polyunsaturated fatty acids (PUFAs), are generated and orchestrate the resolution of inflammation by promoting macrophage mediated clearance of cellular debris and counteracting the effects of pro-inflammatory cytokines [14] .

A c c e p t e d M a n u s c r i p t 5 The SPMs are derived from omega-6 (linoleic acid (LA), arachidonic acid (AA)) or omega-3 (eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA)) substrates via the COX, LOX and cytochrome P450 pathways [14] (SI Figure 1) . Knowledge of the impact of SARS-CoV-2 infection on the pathways that drive the resolution of inflammation will provide crucial new mechanistic insight and potential novel avenues for treatment [15] [16] [17] .

The most well characterised SPMs are the resolvins (Rvs), protectins (PDs), and maresins (MaRs), which halt the transition from acute to chronic inflammation preventing pathogenesis [18] . 17(S)-hydroxy Docosahexaenoic acid (17-HDHA), a substrate for the generation of the D series resolvins [14] , enhances the adaptive immune response in a preclinical model of influenza [19] , both 17-HDHA and resolvin D1 enhance B cell production and promote B cell differentiation towards an antibody secreting phenotype [20] ). The epoxyeicosatrienoic acids (EETs), derived from AA via the CYP450 pathway (SI Figure 1) , also mediate resolution of inflammation [21, 22] , down-regulating inflammatory transcription factors such as NF-kB [23] , curtailing the induction of COX2 and production of cytokines [24] . Current knowledge of the consequences of SARS-CoV-2 infection on endogenous levels of SPMs and EETs is in its infancy [11, [25] [26] [27] . Building a comprehensive picture of the impact of SARS-CoV-2 infection upon circulating levels of bioactive lipid will aid understanding of the therapeutic potential of the resolution pathways for SARS-COV-2 infection [15, 16, 28] . Our aims were to 1) compare serum levels of a range of SPMs and pro-inflammatory bioactive lipids between patients admitted to hospital with SARS-CoV-2 infection and an age-matched control group, 2) determine the potential relationship between levels of these A c c e p t e d M a n u s c r i p t 6 bioactive lipids and levels of anti-nucleocapsid and anti-spike antibody binding, markers of the production of an adaptive immune response [29] and 3) investigate outcomes following infection.

Serum samples obtained from 50 inpatients admitted to Nottingham University Hospitals NHS Trust Queen's Medical Centre with symptomatic RT-PCR confirmed SARS-CoV-2 infection were collected as diagnostic specimens for clinical chemistry testing. Excess sera were provided anonymously for research purposes, and was the only biofluid available during the height of the pandemic. Baseline serum samples from the iBEAT-OA cohort study (n=94) were used as age and sex matched SARS-CoV-2 negative controls [31] . As these samples were collected pre-pandemic a lack of SARS-CoV-2 infection was not confirmed. The iBEAT-OA cohort had a confirmed diagnosis of osteoarthritis, these samples were used as a control group as they were age and sex matched and also had a range of co-morbidities (SI Table 1 ). Ethical approval was obtained from the Research Ethics Committee (ref: 18/EM/0154) and the Health Research Authority (protocol no: 18021).

Serum bioactive lipids were extracted and measured using our published liquid chromatographymass spectrometry (LC-MS/MS) quantification method for the major classes of pro-and antiinflammatory lipid molecules, which has been updated to include SPMs and their precursor molecules [32] . 44 bioactive lipids were quantified, detailed methods are in Supplementary Information and SI Table 2 .

Anti-nucleocapsid and anti-spike quantitative binding assays were performed on serum samples using ELISA following the protocol described by Tighe et al (2020) [29] . Levels of C reactive protein (CRP) were measured in clinical diagnostic tests (mean 172.9 levels ranged from 11-489). The median time between sample collection for CRP measurement and collection of serum for the measurement of bioactive lipids, anti-nucleocapsid and anti-spike antibody binding was 5 days. M a n u s c r i p t 7

GraphPad Prism (Version 8.2.1) was used. In some cases, patients were stratified into three age groups (<60, 61-74, & >75 years). Groups were assessed for normal distribution using D'Agostino & Pearson test and evaluated for significant changes between groups using Kruskal-Wallis test with multiple comparisons corrected for using Dunn's test. Multivariate analysis using Metaboanalyst 4.0 (https://www.metaboanalyst.ca/) [33] including principal component analysis (PCA) was performed. Partial least square discrimination analysis (PLS-DA) was used to identify the lipid mediator clusters. A cross validation analysis was used to validate the PLS-DA model based on accuracy, R2 and Q2 scores and a permutation test. Variable Importance in Projection (VIP) scores greater than 1 were recognized as playing a key role in cluster differentiation (SI Figure 4 & SI Table 3 ).

Serum samples collected from hospital inpatients (22 female, 28 male) with confirmed diagnosis of Sars-CoV-2 (SARS-CoV-2) were studied (SI Table 1 ). 30 patients recovered and were discharged, 20 died, and 25 spent time in ICU during hospitalisation (SI Table 1 ).

SARS-CoV-2 serum had high concentrations of omega-6 derived pro-inflammatory lipids and omega-6 and omega-3 derived anti-inflammatory SPM lipids (Table 1) , which were significantly increased compared to age and sex matched control serum. In control serum, comparable to the healthy population [34] , many of the anti-inflammatory SPM lipids were not detectable, or present at very low levels. PLS-DA analysis of all lipids quantified identified contributors to the separation between the SARS-CoV-2 and control serum ( Figure 1A ). 22 lipids from seven classes of lipids had a VIP score >1 and statistically underpinned the separation between the two clusters ( Figure 1B) . Although serum concentrations of the omega-3 ( Figure 1C ) and omega-6 ( Figure 1E ) were similar between the SARS-CoV-2 and control serum, concentrations of the down-stream bioactive lipids were markedly increased in SARS-CoV-2 serum. There were substantially higher levels of the anti-inflammatory SPMs (17-HDHA, RvD4, LXA4, LXA5) ( Figure 1D ), PGD2 ( Figure 1F ), HETEs (1G), 11,12-EET ( Figure 1H ) and endocannabinoids (2-AG, AEA) ( Figure 1J ) in SARS-CoV-2 serum, compared to control serum. Our findings support a profound mobilisation of pro-resolving and pro-inflammatory mediators following SARS-CoV-2 infection.

PLS-DA analysis revealed a clear separation between the SARS-CoV-2 and control serum for the three age groups (SI Figure 2A-C) . Overall, the majority of the lipids contributing to the separation between the SARS-CoV-2 and control serum were the same for the three age groups studied (SI Figure 2D ). This was confirmed by a univariate analysis (Figure 2 , SI Tables 4 & 5) . Overall, the ability to mount a pro-resolution response was not markedly altered by age in our study. Analysis of potential sex differences in the levels of the various omega-6 derived pro-inflammatory lipids and omega-6 and omega-3 derived anti-inflammatory SPM lipids in the SARS-CoV-2 serum versus control was undertaken. However, there were no significant differences between males and females for any of the lipids analysed (data not shown). M a n u s c r i p t 8 Changes in the flux through enzymatic pathways generating SPMs may provide insight into novel treatments for Sars-CoV-2 infection. Serum levels of DHA and the downstream metabolites, 17-HDHA and 14-HDHA, were correlated in both SARS-CoV-2 and control serum ( Figure 3A-B) . However, levels of EPA and 18-HEPE were correlated in SARS-CoV-2 serum but not control serum, suggesting a potential upregulation of the E series resolving pathway following infection ( Figure 3C ).

Serum levels of AA were within a healthy range in the control group [35] , but were elevated in SARS-CoV-2 serum across all age groups (SI Figure 5A) . Levels of the anti-inflammatory EETs and the downstream metabolites (DHETs) are presented both individually and as a ratio to reflect the activity of the sEH pathway ( Table 1 ). The ratio of 11,12-EET:11,12-DHET was significantly increased in SARS-CoV-2 serum, compared to matched control serum (SI Figure 5B ). There were some differences in the ratios of 8,9-EET:8,9-DHET and 14,15-EET:14,15-DHET but these were less consistent across the age groups for the two groups (Table 1 ). In the SARS-CoV-2 serum, levels of AA were correlated with all EETs measured ( Figure 4A-D) , whereas in the control serum AA was only correlated with 8,9-EET and 11,12-EET ( Figure 4B & 4C) . These data suggest changes in the flux through the sEH pathway following SARS-CoV-2 infection, worthy of further future investigation.

Anti-SARS-CoV-2 antibody binding to the nucleocapsid protein was interrogated using a reference antigen. Viral sequence data, where available, confirmed that the variants circulating in our cohort were either the Hu-1 strain, or the variant defining the 20B lineage (defined by the spike D614G variant), with no variability in nucleocapsid amino acid sequence [29] . There was a range of levels of anti-nucleocapsid (0.15 to 3.11 OD450) and anti-spike antibody (0.115-3.067 OD450) in the SARS-CoV-2 group.

Based on the ranges, patients were divided into three groups of anti-nucleocapsid response (<0.5 (n=16), 0-5-2.5 (n=11) and >2.5 (n=22) OD450) and levels of bioactive lipids between the groups compared. Serum levels of 14-HDHA, 11,12-EET and 8-, 12-, and 20-HETE were significantly higher in those samples with an anti-nucleocapsid response >2.5 (SI Figure 7) . Serum levels of AA, 8-HETE, DHA, EPA, 14-HDHA and 18-HEPE were positively correlated with anti-nucleocapsid levels ( Table 2) .

Based on the range of anti-spike antibody binding, patients were separated into two groups: low (<0.5, n=26) and high (>0.5, n=26), the subset of patients who died had significantly lower levels of anti-spike antibody binding (SI Figure 6 ). Levels of 18-HEPE, 17-HDHA, RvD4 and 14,15-EET were significantly higher in patients with an anti-spike antibody value >0.5 ( Figure 5 ). There were statistically significant positive correlations between these lipids and anti-spike antibody binding for the entire group of patients (Table 2) . Of the lipids measured in the SARS-CoV-2 cohort, 12-, 16-, and 20-HETE; TXB2; PGs; DHETs; ECs; and 5,6-, 8,9-, and 11,12-EET were not correlated with levels of either anti-nucleocapsid or anti-spike antibody binding values ( Table 2) .

Analysis of serum levels of bioactive lipids early in the infection and the clinical outcome identified that levels of LA and 5,6-DHET were significantly lower in SARS-CoV-2 infected patients who died, and the ratio of 5,6-EET:5,6-DHET was higher in those patients that died compared to those that survived (SI Table 6 ). M a n u s c r i p t 9

SARS-CoV-2 infection was associated with robust increases in serum levels of both omega-6 and omega-3 derived bioactive lipids which have well-described pro-and anti-inflammatory roles [36] . Significant increases in serum levels of pro-inflammatory lipids included PGE2 (1.5 fold), TXB2 (3 fold), LTB4 (10 fold), 5-HETE (159 fold), and 13-HODE (20 fold) in the SARS-CoV-2 group, compared to the age matched control group. For the anti-inflammatory bioactive lipids and precursors, there was a 47-fold increase in levels of the SPM precursor 17-HDHA in the SARS-CoV-2 group. Serum levels of the SPMs RvD4 and Mar2 are normally close to, or below, the limits of detection in the healthy population [37] , but were present in the SARS-CoV-2 group. Substantial increases in levels of some of the EETs (11,12-EET: 285 fold increase; 8,9-EET: 3.5 fold increase) in the SARS-CoV-2 group suggest a concerted anti-inflammatory response via multiple enzymatic pathways following SARS-CoV-2 infection. Our data support a robust activation of the resolution pathways following SARS-CoV-2 infection, irrespective of patient age, which was not influenced by age or gender. These data, and an earlier report of elevated levels of RvE3 [11] , point to a complex pathophysiological response to SARS-CoV-2 infection, which may be amenable to pharmacological intervention and provide new targets for treatment.

Our findings are consistent with the report of higher levels of plasma and serum SPMs and increased expression of related enzymatic pathways in peripheral blood monocyte subsets in 19 patients infected with SARS-CoV-2 [26] . Increased levels of pro-inflammatory bioactive lipids and antiinflammatory SPMs, including RvD4, D5, D2, D1 and PDX have also been reported in bronchoalveolar lavage from SARS-CoV-2 patient [25] . SPMs are already known to modulate acute lung injury and respiratory distress syndrome, supporting these findings following SARS-CoV-2 infection. Antibodies generated by B cells are critical to anti-viral immunity. The D series precursors and resolvins, including 17-HDHA, enhance human B cell antibody production by promoting differentiation towards an anti-body secreting phenotype [20] . In a pre-clinical murine model of influenza immunization, 17-HDHA treatment increased antigen specific antibody responses and protected against live influenza virus infection [19] . These data suggest that a robust generation of 17-HDHA following infection may not only act to counter pro-inflammatory responses, but also facilitate the response of B cells to mount an antibody response. To date there are no studies of the effects of the SPMs on SARS-CoV-2 infection in patients, however, it has been reported that both RvD1 and RvD2 have beneficial effects on inflammatory responses in SARS-CoV-2 infected macrophages [27] . There was a broad range of anti-nucleocapsid and anti-spike responses in the SARS-CoV-2 group, indicative of adaptive immune response to infection. Consistent with a larger study [29] , increased anti-spike responses were associated with improved clinical outcome. SARS-CoV-2 patients with higher anti-spike responses (>0.5) had significantly higher levels of anti-inflammatory / resolution molecules (18-HEPE, 17-HDHA, 14-HDHA, Resolvin D4, Maresin 2, 14, 15-EET), which either directly mediate resolution of inflammation or are metabolites in the resolution pathways, as well as some pro-inflammatory lipids (LTB4, 5-, 8-, 9-, 11-, & 15-HETE and 9-, & 13-HODE). Levels of PUFA substrates were not substantially altered by SARS-CoV-2 infection or age, thus it is unlikely that substrate and therefore diet is major determining factor in the resolution response to SARS-CoV-2 infection. The strong correlations between PUFAs and their downstream SPM pathway metabolites in the SARS-CoV-2 infection group suggests that these enzymatic pathways are upregulated by this infection, particularly evident for the E series pathway. Our findings support future studies of the A c c e p t e d M a n u s c r i p t 10 relationship between the antibody response to SARS-CoV-2 infection, activation of the resolution pathways and clinical outcome in a larger cohort of patients.

Current evidence suggests that treatments for SARS-CoV-2 infection, alongside vaccination, will remain a priority in the immediate future. Identification of the critical steps involved in the upregulation of these anti-inflammatory pathways may be instructive for the development of interventions aimed at dampening the inflammatory response or promoting the clearance of the inflammation arising from SARS-CoV-2 infection. Dexamethasone has been identified as an important treatment to promote recovery from SARS-CoV-2 infection. Dexamethasone increased SPM levels in a small number of SARS-CoV-2 infected patients [26] , healthy volunteers [38] and in allergic airway inflammation [39] . Future investigation of the potential contribution of SPMs to the beneficial effects of dexamethasone in patients with SARS-CoV-2 infection in a larger cohort will improve further our understanding of the potential mechanisms of action of this treatment.

There are a number of study limitations. Serum samples were collected from patients hospitalised with SARS-CoV-2 for clinical diagnostic tests during the first wave of the pandemic in the UK. Due to the clinical pressures within the system at the time, some clinical data, such as BMI and medication, were not collected. It is known that levels of SPMs are decreased with increased BMI, which could potentially contribute to SARS-CoV-2 related morbidities and mortalities [40] . Although our analysis of SARS-CoV-2 serum (the only biofluid available at the time) may impact upon the absolute levels of the lipids measured, this was controlled for in our use of SARS-CoV-2 negative serum to mitigate any major impact. Data relating to whether a patient was admitted to intensive care was available for these samples, however clinical decision making was related to multiple factors beyond the severity of the infection and therefore further analysis of potential impact has not been performed. Serum samples were collected within the first few days of hospital admission and represent a snapshot of the anti-nucleocapsid and anti-spike response and the lipid levels at a point in time. However, levels of antibodies change over time and we do not have matched longitudinal data. The antinucleocapsid and anti-spike signal provides an indication of the potency of the adaptive immune response following infection. The viral genome sequencing data available for these patients indicated that the nucleocapsid amino acid sequence was completely conserved between infections. While it is possible that there may be mismatches between the antigen used in our assay and the strain of infecting virus that mean that antibodies are present which are undetected by our assay, at the time of sampling there was minimal genetic diversity in UK isolates[www.nextrstrain.org]. Nevertheless to mitigate against this, we used ELISAs against two antigens.

In summary, our findings highlight that SARS-CoV-2 infection can lead to very robust activation of the pathways that generate the specialised pro-resolving molecules and other pro-and antiinflammatory bioactive lipids. This new knowledge supports the future investigation of these pathways which may inform the development of novel anti-inflammatory treatments for SARS-CoV-2 infection. Furthermore, these new datasets provide us opportunities to explore further the underlying molecular pathways that regulate the resolution pathways in humans, with the goal of identifying novel approaches for the development of new therapeutics for other infections and chronic inflammatory diseases. 

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study

COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participants

Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

COVID-19: The Immune Responses and Clinical Therapy Candidates

Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Chemokines and eicosanoids fuel the hyperinflammation within the lungs of patients with severe COVID-19

Cutting edge: Severe SARS-CoV-2 infection in humans is defined by a shift in the serum lipidome, resulting in dysregulation of eicosanoid immune mediators

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Prevalence of Co-infection at the Time of Hospital Admission in COVID-19 Patients, A Multicenter Study

Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators

Pro resolving inflammatory effects of the lipid mediators of omega 3 fatty acids and its implication in SARS COVID-19

Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

Specialized pro-resolving mediators: endogenous regulators of infection and inflammation

The specialized proresolving mediator 17-HDHA enhances the antibody-mediated immune response against influenza virus: a new class of adjuvant?

Specialized proresolving mediators enhance human B cell differentiation to antibodysecreting cells

Lipidomic Profiling of Influenza Infection Identifies Mediators that Induce and Resolve Inflammation

Epoxyeicosatrienoic Acid as Therapy for Diabetic and Ischemic Cardiomyopathy

Soluble Epoxide Hydrolase Inhibitor Suppresses the Expression of Triggering Receptor Expressed on Myeloid Cells-1 by Inhibiting NF-kB Activation in Murine Macrophage

Soluble Epoxide Hydrolase and Epoxyeicosatrienoic Acids Modulate Two Distinct Analgesic Pathways

High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients

Disrupted Resolution Mechanisms Favor Altered Phagocyte Responses in Covid-19

Resolvin D1 and D2 reduce SARS-CoV-2-induced inflammatory responses in cystic fibrosis macrophages

Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications?

Potent anti-SARS-CoV-2 Antibody Responses are Associated with Better Prognosis in Hospital Inpatient COVID-19 Disease. MedRxiv [Preprint] 2020. 30. consortium TC-GUC-U. An integrated national scale SARS-CoV-2 genomic surveillance network

Evaluating the efficacy of Internet-Based Exercise programme Aimed at Treating knee Osteoarthritis (iBEAT-OA) in the community: a study protocol for a randomised controlled trial

Simultaneous tissue profiling of eicosanoid and endocannabinoid lipid families in a rat model of osteoarthritis

Using MetaboAnalyst 4.0 for Metabolomics Data Analysis, Interpretation, and Integration with Other Omics Data. Computational Methods and Data Analysis for

Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation

Correction: Comprehensive profiling of plasma fatty acid concentrations in young healthy Canadian adults

Lipid mediators in immune regulation and resolution

Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue

Antiemetic doses of dexamethasone and their effects on immune cell populations and plasma mediators of inflammation resolution in healthy volunteers

Dexamethasone induces ω3-derived immunoresolvents driving resolution of allergic airway inflammation

The authors thank Professors David Walsh and John Gladman for their advice in preparation of the manuscript. The authors also thank Dr Divyateja Hrushikesh and colleagues from the Queens Medical Centre for providing samples and clinical data.

The source of funding had no influence over the design or conduct of the study.

This research was funded by the NIHR Nottingham Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

The authors declare no conflicts of interests.

A c c e p t e d M a n u s c r i p t 12 A c c e p t e d M a n u s c r i p t 14 A c c e p t e d M a n u s c r i p t